{
    "nctId": "NCT03457467",
    "briefTitle": "Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer",
    "officialTitle": "Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Overall survival (OS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: \u2265 18 years old women; 2. Histologically confirmed breast cancer; 3 weeks before enrollment ECOG PS score: 0-2 points; 4. systemic metastasis lesions \u2264 5, Stereotactic body radiotherapy before receiving medical treatment to achieve partial relief or stable disease; 5. Appropriate hematological parameters and liver and kidney function: absolute neutrophil \u2267 1.5 \u00d7 109 / L; platelet count \u2267 75 \u00d7 109 / L; serum total bilirubin \u2266 1.5 \u00d7 upper limit of normal; AST and ALT \u2266 2.5 \u00d7 upper limit of normal (if liver dysfunction) 6. Subject voluntarily joined the study and signed the informed consent form.\n\nExclusion Criteria:\n\n1. After the above image examination of the whole body metastasis lesions \u2265 6;\n2. Have received one or more palliative chemotherapy regulators failed;\n3. Patients with a high risk of bleeding: active gastric digestive ulcer in the stomach with fecal occult blood (++); those with a history of melena and / or vomiting within 3 months; persons with abnormal coagulation and bleeding tendency; 3-4 grade hypertension patients;\n\n5. Renal insufficiency 3 and above patients; 6. Hand-foot syndrome \u2265 3 or more patients; 7. There are uncontrolled concomitant diseases in the first 6 months of the study, including unstable angina pectoris, acute myocardial infarction, cerebrovascular accident and so on; 8. Pregnant or breastfeeding patients, or who have fertility without taking contraceptive measures; 9. A history of malignancy, but disease-free survival of more than 5 years; 10. Concurrent with other anti-cancer therapies or other interventional clinical trials; 11. Patients unable to follow the study due to psychological, family-living social reasons",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}